JAMA Oncology : Impact Factor & More
eISSN: 2374-2445pISSN: 2374-2437
Share this on:
Key Metrics
CiteScore 
44.4
Eigenfactor
0.05 - 0.1
Impact Factor
>= 25
Scite Index
0.85 5-Year SI
SJR
Q1Oncology
SNIP
7.17
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on JAMA Oncology
JAMA Oncology Journal Specifications
Indexed in the following public directories
Web of Science 
SJR
| Overview | |
| Publisher | AMER MEDICAL ASSOC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2015 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in JAMA Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in JAMA Oncology
Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast Cancer
- 25 Jun 2026
- JAMA Oncology
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer
- 25 Jun 2026
- JAMA Oncology
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
- 25 Jun 2026
- JAMA Oncology
Three-Body Problem at Digital Frontiers
- 25 Jun 2026
- JAMA Oncology
One Ovary
- 18 Jun 2026
- JAMA Oncology
Error in Open Access License
- 18 Jun 2026
- JAMA Oncology
Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast Cancer
- 25 Jun 2026
- JAMA Oncology
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer
- 25 Jun 2026
- JAMA Oncology
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
- 25 Jun 2026
- JAMA Oncology
Three-Body Problem at Digital Frontiers
- 25 Jun 2026
- JAMA Oncology
One Ovary
- 18 Jun 2026
- JAMA Oncology
Error in Open Access License
- 18 Jun 2026
- JAMA Oncology
FAQs on JAMA Oncology
How long has JAMA Oncology been actively publishing? 
What is the publishing frequency of JAMA Oncology?
How many articles did JAMA Oncology publish last year?
What is the eISSN & pISSN for JAMA Oncology?
What is Citescore for JAMA Oncology?
What is SNIP score for JAMA Oncology?
What is the SJR for JAMA Oncology?
Who is the publisher of JAMA Oncology?
